LON:EAH

ECO Animal Health Group Interim Earnings Results & Report

ECO Animal Health Group logo
GBX 81.15 -5.85 (-6.72%)
As of 11:11 AM Eastern

ECO Animal Health Group reported Interim earnings on December 1, 2025. The company reported EPS of -GBX 0.54.

Earnings Announcement Details

Quarter
Interim
Report Date
Time
Before Market Opens

ECO Animal Health Group EPS Results

Actual EPS
-GBX 0.54
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ECO Animal Health Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

ECO Animal Health Group Interim Earnings FAQ

ECO Animal Health Group (LON:EAH) reported earnings of -GBX 0.54 per share for Interim. The report was announced on Monday, December 1, 2025.

ECO Animal Health Group Earnings Headlines

FDA clears next-gen therapy with 10 to 40 times greater potency
Time-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.tc pixel
Didier Branellec appointed Non-Executive Director
See More ECO Animal Health Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ECO Animal Health Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ECO Animal Health Group and other key companies, straight to your email.

About ECO Animal Health Group

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline. Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide. Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

View ECO Animal Health Group Profile